Alternate Cancer Remedies
fairs department of SKI: “(1) None of these patients responded posi- tively to hydrazine sulfate, and (2) some of the patients developed neurotoxicity [nerve dam- age], apparently due to the administration of this drug. “Based on these findings, therefore, Sloan- Kettering Institute is no longer treating patients with hydrazine sulfate, nor are we conducting any further experiments with it at the present time.”—SKI Statement, July 25, 1974.
Calbiochem, Inc., a California drug company which had been interested in marketing it, imme- diately drew back, correctly declaring, that hy- drazine sulfate was in the public domain and thus unpatentable. In other words, like gold- enseal, chaparral, apricot kernels, pau d’arco tea, and vitamin C, there were no big profits to be made from it. “We saw absolutely no place to go with it,” he said (David M. Rorvik, “Who Wrote the American Cancer Society’s Denunciation of Hydrazine Sulfate” Alicia Patterson Foundation Newslette , New York, November 29, 1976).
In March 1976, the American Cancer Society placed the substance on its list of unproved meth- ods.
In early 1979, NCI invited Dr. Michael L. Gershanovich, director of medical oncology, Petrov Research Institute of Oncology, Leningrad, to come to the United States and describe his four-year study of 225 patients on hydrazine sulfate.
While crude hydrazine sulfate can be toxic, the form used in cancer treatment differs from industrial grade versions in that it has been highly purified.
Hydrazine sulfate has been shown to be a use- ful chemical compound in eliminating cancer tis- sue. It reduces lean tissue wasting (cachexia) and improves the abnormal glucose and insu- lin levels common among cancer patients.
The normal dosage is one 60-mg tablet, taken three times a day. One hundred 60-mg tablets, enough for a month’s supply, costs about $25.
Although not permitted to be sold in the U.S., it can be ordered from overseas companies by mail order, or from Mexican clinics using it (such as Hospital Santa Monica, 4100 Bonita Road, Bonita, CA 91910 Ph: (800) 359-6547 / (619) 428-1147)
____________________ TIBOR HAJITO, M.D., 1968
Note to researchers: The use of the plant, mistletoe, should be researched, in relation to its cancer fighting characteristics. The pioneering work of Franz should built upon.
Working Summary: Earlier in this book (on page 30), forty anti-cancer herbs were listed. Here is a closer look at one of them. Both mistletoe and its derivative (Iscador) could have side effects, so care must be taken in their utilization.
Dr. Hajito has spent over 20 years administer- ing mistletoe to cancer patients, with remarkable success. Here is the mistletoe story:
But, after arriving in America, Gershanovich was suddenly denied permission to speak at the May 1979 New Orleans meeting of the American Association for Cancer Research. However, the mis- take had not been caught early enough, and ab- stracts (a summary) of Gershanovich’s planned talk were printed as abstract #969 in the Proceed- ings of the AACR.
European mistletoe (Viscum album) has been used to treat sicknesses for as long as any- one can remember. About 2,000 years ago, Pliny the Elder said mistletoe was a remedy for ma- lignancies. It has been used ever since. Actu- ally, the plant is unusual in that it lives on trees, taking water and minerals from them, yet return- ing sugar to the host tree!
From 1984 to 1990 and beyond, Rowan T. Chlebowski, M.D., Ph.D., and his associates at UCLA in Los Angeles began publishing a series of reports documenting the ability of hydrazine sul- fate to prevent weight loss in cancer.
They found that critically ill patients showed only marginal response, but those in better condi- tion when the treatment was started did better. After a year of treatment, 42% of those taking hy- drazine sulfate were alive, compared to 18% of those who did not receive it.
The use of this compound helps patients feel better within two or three weeks. But it occasion- ally can have mild side effects, including mild numbness of the fingers and toes, nausea, vomit- ing, and slight drowsiness. Gold found that this could be reduced or eliminated by taking vitamin
Dr. Hajito of the Lucas Clinic Laboratory of Immunology in Arlesheim, Switzerland, has come to the conclusion that mistletoe does two things in the body at the same time: It inhibits tumor growth while stimulating the immune system. In support of his work, Hajito has written many re- ports in scientific journals.
A number of researchers and physicians have worked with the substance, but generally in the form of Iscador. This is the trade name for the oldest and most widely used mistletoe preparation. Manufactured by Weleda AG (a Ger- man and Swiss chemical company), Iscador is used more in Europe than on any other continent. It is used a lot in Britain.
The entire plant is ground up and made into a watery extract. Next it is fermented with the